[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584444":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"rheumatoid arthritis grups",null,"It includes females and males over the age of 50 who meet the RA diagnostic criteria according to the ACR\u002FEULAR 2010 criteria.",[13],"Diagnostic Test: Osteosarcopenia in Patients with Rheumatoid Arthritis",{"label":15,"type":10,"description":16,"interventionNames":17},"healty control grups","It includes females and males over the age of 50 who do not meet the exclusion criteria.",[18],"Diagnostic Test: Osteosarcopenia in Healthy Control Group",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","Osteosarcopenia in Patients with Rheumatoid Arthritis","The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. Both the prevalence of osteosarcopenia and the subgroups of sarcopenia will be compared with the healthy control group. Through this comparison, we will explain the relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the changes in fall and fracture risk using various questionnaires and tests.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Osteosarcopenia in Healthy Control Group","The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. The relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the risk of falls and fractures will be evaluated using various questionnaires and tests.",[15],[30],{"name":31,"affiliation":32,"role":33},"İlhan ç KAYA","Konya Beyhekim Training and Research Hospital Physical Medicine and Rehabilitation Clinic","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"ilhan ç KAYA","CONTACT","09005377889686","icaglar.kaya@gmail.com",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":10,"cosmosGeoPoint":47,"geoPoint":52,"contacts":10},"RECRUITING","Konya","Selçuklu","42000","Turkey (Türkiye)",{"type":48,"coordinates":49},"Point",[50,51],32.48464,37.87135,{"lat":51,"lon":50},{"type":33,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"ilhan çağlar kaya","DOCTOR","100584444","rheumatoid-arthritis-and-osteosarcopenia-associated-factors-100584444",false,"NCT06889415","Rheumatoid Arthritis and Osteosarcopenia: Associated Factors","The Frequency of Osteosarcopenia in Patients With Rheumatoid Arthritis and the Factors Affecting the Sarcopenia-osteoporosis Relationship","Inclusion criteria:\n\n1. Being diagnosed with RA according to the ACR\u002FEULAR 2010 criteria\n2. Being a female or male over the age of 50\n3. Having the mental and physical capacity to complete the study questionnaires and tests\n4. Providing voluntary consent to participate in the study by signing the Informed Consent Form\n\nExclusion Criteria:\n\n1. Having an acute illness\u002Fdisability or significant cognitive impairment that prevents understanding and performing the required tests\n2. Having thyroid or parathyroid disease, uncontrolled diabetes, Cushing's syndrome, anemia.\n3. History of malignancy\n4. Severe cardiovascular disease, enal failure, advanced-stage COPD, decompensated liver disease\n5. History of gastrointestinal (GIS) surgery\n\n7-Having another coexisting autoimmune\u002Finflammatory rheumatic disease (e.g., SLE, Ankylosing Spondylitis, etc.), psoriatic arthritis, vasculitis, familial Mediterranean fever...)\n\n8-Having severe\u002Fsymptomatic hand osteoarthritis and\u002For deformities\n\n9-Severe\u002Fsymptomatic osteoarthritis in the knee, lumbar, hip, or ankle region\n\n10-Having Carpal Tunnel Syndrome, De Quervain, lateral epicondylitis, cubital tunnel syndrome or a history of traumatic hand injury\n\n11-Having a significant neurological disease, stroke, MS, myopathy, Parkinson's disease, radiculopathy\u002Fpolyneuropathy\u002Fbrachial plexopathy or others nerve root compressions\n\n12-History of surgical intervention on the upper and lower extremities or spine\n\n13-Having severe kyphosis or scoliosis\n\n14-Having any others disease causing balance disorders (neurological, orthopedic, metabolic, etc.)\n\n15-Having a major\u002Fsignificant psychiatric disorder (based on the medical history, and hospital records)\n\n16-Current use of androgens or estrogens\n\n17-Having prostheses, being fully dependent, or immobilized",true,"ALL","50 Years",{"count":67,"type":68},200,"ESTIMATED","1 Day","OBSERVATIONAL","Our study is a cross-sectional study, and its aim is to compare and analyze the prevalence of sarcopenia and osteoporosis in patients with rheumatoid arthritis (RA) with a control group and to reveal the impact of sarcopenia on osteoporosis, fall risk, and fracture risk. This prospective cross-sectional study will include 100 rheumatoid arthritis patients and 100 healthy controls, matched for age and sex. Patients will be consecutively and meticulously enrolled based on inclusion and exclusion criteria.\n\nA detailed medical history and examination will be performed on the patients, and their clinical and sociodemographic characteristics will be recorded. Blood tests for RA (RF, Anti-Cyclic Citrullinated Peptide (anti-CCP), CRP, ESR) and disease activity levels (DAS28) will be recorded. The prevalence of osteosarcopenia will be assessed in both the RA and healthy control groups.These groups will be evaluated using various scales and tests (including power, performance tests) including musculoskeletal ultrasonographic measurements and clinical functional assessment tests. he sarcopenic group will be categorized based on the level of sarcopenia, according to the new ISarcoPRM criteria (non-sarcopenic, dynapenic, sarcopenic, and severe sarcopenic). Osteosarcopenia will be evaluated for both groups, and the collected data will be analyzed with primary and secondary outcomes. The analysis will explore the potential relationships between rheumatoid inflammation, sarcopenia, and osteoporosis.",[73,74,75],"Osteosarcopenia","Rheumatoid Arthritis (RA)","Sarcopenia",[77,78,79,80],"osteosarcopenia","sarcopenia","Ultrasonography","rheumatoid arthritis","2025-07-05",{"date":83,"type":84},"2025-07-10","ACTUAL",{"date":86,"type":84},"2023-08-15",{"date":88,"type":68},"2025-11-30",{"name":5,"class":6},1]